Výsledky vyhledávání

Docetaxel Plus 5-Fluorouracil in Locally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Autor: M. Mallard-Carre, G. Calais, Nicole Tubiana-Mathieu, M. H. Philippi, J. P. Dutin, Dominique Genet, Didier Cupissol, B. Bendahmane, P. Bontemps, Hugues Bourgeois

Publikováno v: American Journal of Clinical Oncology. 27:472-476

This phase II study evaluated docetaxel-5-fluorouracil (5-FU) in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Patients were divided into 2 cohorts--those previously treated with chemotherapy and those nonp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db5830e42392d7a2ca52f05dcdda90ce
https://doi.org/10.1097/01.coc.0000136017.13633.b0

Zobrazit plný text záznamu

Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC125) specific for CA125 antigen

Autor: Pierre Fumoleau, Jean-François Chatal, P. Bourguet, A. Loboguerrero, P. Peltier, J.-Y Hérry, J.-P. Dutin, J.-C. Liehn, J. P. Vuillez

Publikováno v: Annals of Oncology. 4:307-311

Summary Background A progressive rise in serum CA 125 concentration during follow-up monitoring of ovarian cancer after treatment of primary tumor is suggestive of a recurrence. Patients and methods A study was carried out in 19 patients with suspect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e924ce76923d56ea86f7f901fb37f19b
https://doi.org/10.1093/oxfordjournals.annonc.a058488

Zobrazit plný text záznamu

[Efficacy of the combination of mitomycin, ifosfamide and cisplatin with irradiation for the treatment of cerebral metastasis in non small cell lung carcinoma]

Autor: I, Cumin, H, Lacroix, M, Mahé, J P, Dutin, G, Dabouis

Publikováno v: Bulletin du cancer. 82(1)

We initiated prospective study testing efficacy of multidrug chemotherapy (cisplatin, ifosfamide, mitomycin) with irradiation in brain metastases of non small cell lung cancer at first diagnosis. Among 22 patients we obtained ten objective local resp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b1658024ac0b2407d1929a90ce2c95e9
https://pubmed.ncbi.nlm.nih.gov/7742617

Zobrazit plný text záznamu

Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, Saclay

Autor: P, Peltier, J P, Dutin, J F, Chatal, P, Fumoleau, P, Bourguet, J C, Liehn, J P, Vuillez, J Y, Hérry, A, Loboguerrero

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 4(4)

A progressive rise in serum CA 125 concentration during follow-up monitoring of ovarian cancer after treatment of primary tumor is suggestive of a recurrence.A study was carried out in 19 patients with suspected recurrence of a previously treated ova

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::01cacb17f2fc64b69761bfeab6d4aa05
https://pubmed.ncbi.nlm.nih.gov/8518221

Zobrazit plný text záznamu

Correlative imaging study in the diagnosis of ovarian cancer recurrences. The INSERM Research Network (Nantes, Rennes, Reims, Villejuif, Saclay), France

Autor: P, Peltier, K, Wiharto, J P, Dutin, J F, Chatal, P, Bourguet, J C, Liehn, J P, Vuillez, J Y, Hérry, A, Loboguerrero

Publikováno v: European journal of nuclear medicine. 19(12)

A correlative imaging study was carried out in 61 female patients previously treated for ovarian carcinoma. Upon suspicion of recurrence, abdominopelvic immunoscintigraphy (IS) using F(ab')2 fragments of indium-111-labelled OC 125 monoclonal antibody

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9407ae6fa107c710346378946ff5f476
https://pubmed.ncbi.nlm.nih.gov/1464352

Zobrazit plný text záznamu

Phase I trial of pegylated liposomal doxorubicin (PLD) and cyclophosphamide (CPM) in patients with relapsed platinum- resistant epithelial ovarian carcinoma (EOC)

Autor: D. Jaubert, Anne Floquet, Véronique Brouste, C. Dupouy, Simone Mathoulin-Pélissier, L. Cany, J. P. Dutin

Publikováno v: Journal of Clinical Oncology. 25:16057-16057

16057 Background: Most patients (pts) with EOC recur despite platinum-taxane based first line chemotherapy. Response to second line chemotherapy is limited, and usually related to time between the end of first line treatment and relapse. For early re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::385f32b1569783d92eba93d7ad42e149
https://doi.org/10.1200/jco.2007.25.18_suppl.16057

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání